In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6

British Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2000, Pages 343-351

  Ko, Jae Wook ^a   Desta, Zeruesenay ^a   Soukhova, Nadia V ^a   Tracy, Timothy ^b   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antiplatelet; Cytochrome P450; Inhibition; Ticlopidine

Indexed keywords

CHLORPROPAMIDE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2C19; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; DEXTRORPHAN; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLITE; FLURBIPROFEN; LEVALLORPHAN; MEPHENYTOIN; MIDAZOLAM; PARACETAMOL; PHENACETIN; PHENACETIN O DEETHYLASE; PHENYTOIN; RECOMBINANT ENZYME; TICLOPIDINE;

ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS; SIMULATION; STEADY STATE;

ANTICONVULSANTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MUSCLE RELAXANTS, CENTRAL; PHENACETIN; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; TICLOPIDINE; TOLBUTAMIDE;

EID: 0034128040     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00175.x     Document Type: Article

References (46)

1. 1 Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
2. 2 Lin HJ, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implication. Clin Pharmacokin 1998; 35: 362-390.
3. 3 McTavish D, Faulds D, Goa KL. Ticlopidine: an update review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs 1990; 40: 238-259.
4. 4 Donahue SR, Flockhart DA, Abernethy DR, Ko J-W. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 1997; 62: 572-577.
5. 5 Donahue SR, Abernethy DR. Ticlopidine inhibition of steady state phenytoin metabolism in humans (abstract). Clin Pharmacol Ther 1998; 63: 183.
6. 6 Lopez-Ariztegui N, Ochoa Sanchez-Migallon MJ, Nevado C, Martin M. Intoxicacion aguda por fenitoina secundaria a interaccion con ticlopidina. Rev Neurol 1998; 26: 1017-1018.
7. 7 Klaassen SL. Ticlopidine-induced toxicity. Ann Pharmacother 1998; 32: 1295-1298.
8. 8 Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol 1996; 53: 1191-1192.
9. 9 Rindone JP, Bryan GH, Ariz P. Phenytoin toxicity associated with ticlopidine administration [letter]. Arch Intern Med 1996; 156: 1113.
10. 10 Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance; a case report. Neurology 1996; 46: 1172-1173.
11. 11 Tateishi T, Kumai T, Watanabe M, Nakura H, Tanaka M, Kobayashi S. Ticlopidine decreases the in vitro activity of CYP2C19 as measured by omeprazole metabolism. Br J Clin Pharmacol 1999; 47: 454-457.
12. 12 Colli A, Buccino G, Cocciolo M, Parravivini R, Elli GM, Scaltrini G. Ticlopidine-theophylline interaction. Clin Pharmacol Ther 1987; 41: 358-362.
13. 13 Brown RI, Cooper TG. Ticlopidine-carbamazepine interaction in a coronary stent patient. Can J Cardiol 1997; 13: 853-854.
14. 14 Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17: 33-38.
15. 15 Knudsen JB, Bastain W, Sefton CM, Allen JG, Dickinson JP. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992; 22: 579-589.
16. 16 Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokin 1994; 26: 347-355.
17. 17 Murray JC, Kelly MA, Gorelick PB. Ticlopidine: a new antiplatelet agent for the secondary prevention of stroke. Clin Neuropharmacol 1994; 17: 23-31.
18. 18 Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P4503A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-4035.
19. 19 Pollard HB, Menard R, Brabdt HA, Pazolzs CJ, Creutz CE, Ramu A. Application of Bradford's assay to adrenal gland subcellular fractions. Anal Biochem 1978; 86: 761-763.
20. 20 Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW, Flockhart DA. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428-437.
21. 21 Ko J-W, Soukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and Lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-862.
22. 22 Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.
23. 23 Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252: 442-447.
24. 24 Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies of flurbiprofen 4'hydroxylation: additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 1996; 52: 1305-1309.
25. 25 Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P4502C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993; 306: 240-245.
26. 26 Broly F, Libersa C, Lhermitte M, Bechtel P, Dupuis B. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 1989; 28: 29-36.
27. 27 Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450, 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-556.
28. 28 Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P4503A (CYP3A) subfamily. Biochem Pharmacol 1994; 48: 173-182.
29. 29 Peter R, Bocker R, Beaune PH, Iwaski M, Guengerich FP, Xang CS. Hydroxylation of chloroxazone as a specific probe of cytochrome P450IIE1. Chem Res Toxicol 1990; 3: 566-573.
30. 30 Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
31. 31 Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 1998; 353: 16-28.
32. 32 Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24: 1401-1403.
33. 33 Shah J, Teitelbaum P, Molony B, Gabuzda T, Massey I. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991; 32: 761-764.
34. 34 Flockhart DA. Drug interactions and the cytochrome P450 system: the role of cytochrome P4502C19. Clin Pharmacokinet 1995; 29(Suppl 1): 45-52.
35. 35 Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450(CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
36. 36 Mankowski DC. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 1999; 27: 1024-1028.
37. 37 Masimirembwa CM, Otter C, Berg M, et al. Heterologous expression and kinetic characterization of human cytochromes P450: Validation of a pharmaceut tool for drug metabolism research. Drug Metab Dispos 1999; 27: 1117-1122.
38. 38 Yasumori T, Chen L, Li Q, et al. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19. Biochem Pharmacol 1999; 57: 1297-1303.
39. 39 Fritz S, Lindner W, Roots I, Frey BM, Kupfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987; 241: 615-622.
40. 40 Mamiya K, Ieiri I, Shimamoto J, et al. The effect of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39: 1317-1323.
41. 41 Levy RH. Cytochrome P450 isoenzymes and antiepileptic drug interactions. Epilepsia 1995; 36(Suppl 5): S8-S13.
42. 42 Betty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39: 305-311.
43. 43 de Boissonnat P, Lorgeril M, Perroux V, et al. A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients. Eur J Clin Pharmacol 1997; 53: 39-45.
44. 44 Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Drug Safety 1998; 19: 89-98.
45. 45 Weisberg LA. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology 1993; 43: 27-31.
46. 46 Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulant Restenosis Study Investigation. N Engl J Med 1998; 339: 1665-1671.